Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
S63845 It is possible that regulation of
2022-10-03

It is possible that regulation of adiposity and glucose homeostasis by GIP are in part mediated by altering leptin levels and/or leptin signaling. However, we are unaware of reports that support this mechanism of action of GIP. In addition, leptin levels in GIP receptor knockout mice [12], [52] and
-
br Conclusions and perspectives In conclusion
2022-10-02

Conclusions and perspectives In conclusion, offering duly validated and highly performing assays for measuring DiXaIs in plasma is a step, but not the final issue. More dedicated and individual assays will continue this innovative development, which witnesses the need for collaboration between co
-
DZNep is a PRC inhibitor that inhibits S adenosylhomocystein
2022-10-02

DZNep is a PRC2 inhibitor that inhibits S-adenosylhomocysteine hydrolase, resulting in cellular accumulation of S-adenosylhomocysteine. S-adenosylhomocysteine is a competitive inhibitor of methyl donor for methyltransferases [38]. DZNep targets EZH2 by reduction in the level of the enzyme H3K27me3 a
-
We addressed the role of
2022-10-01

We addressed the role of GSNOR-mediated T-cell activation in HHcy-accelerated atherosclerosis in vivo by two mouse models. Generated for the first time, GSNOR-/-ApoE-/- double knock-out mice showed decreased atherosclerosis in aortic roots in response to HHcy. The specificity of GSNOR ablation in T
-
ar 165 1 receptor To apply the recently developed GPR ligand
2022-10-01

To apply the recently developed GPR35 ligands to CNS disorders, it is necessary to understand whether GPR35 is expressed by any identified cell types in the ar 165 1 receptor and whether activation or blockade of this receptor has any consequence on the activity of the neuronal circuitry. To this e
-
Intranasal immunization can induce the activation of IgA
2022-10-01

Intranasal immunization can induce the activation of IgA-secreting plasma cell precursors that are present in NALT and induce IgA antibody-secreting cells; these cells express l-selectin (+), allowing migration to the lymphatic nodes, as well as α4β1 (+), CXCR4 (+), and CCR10 (+), which facilitate m
-
By contrast pentameric glycine receptors
2022-09-30

By contrast, pentameric glycine receptors (GlyR) in humans have four functional subunits, α1− α3 and β (Lynch, 2004) whereas the retina of other mammals have an additional α4 subunit (Harvey et al., 2000), and in humans the α4 subunit is considered a pseudogene as it lacks the 4th transmembrane doma
-
There are also data showing potential beneficial effects of
2022-09-30

There are also data showing potential beneficial effects of SGLT2i on non-alcoholic fatty liver disease (NAFLD) [[14], [15], [16], [17]], a hepatic manifestation of the metabolic syndrome that has been linked to type 2 diabetes mellitus (T2DM) development and increased cardiovascular (CV) as well as
-
GK also called hexokinase IV or
2022-09-30

GK, also called hexokinase IV or D, is a glycolytic enzyme that converts Superoxide Dismutase (SOD) Activity Assay Kit to glucose-6-phosphate. GK has unique characteristics compared with those of the ubiquitously expressed hexokinase isoforms I–III, and is predominantly expressed in the pancreas an
-
GK also called hexokinase IV or
2022-09-30

GK, also called hexokinase IV or D, is a glycolytic enzyme that converts Cucurbitacin I to glucose-6-phosphate. GK has unique characteristics compared with those of the ubiquitously expressed hexokinase isoforms I–III, and is predominantly expressed in the pancreas and liver. In pancreatic β-cells,
-
In summary our findings provide the evidence and
2022-09-30

In summary, our findings provide the evidence and the mechanistic understanding of the protective effects of GIP receptor agonist, D-Ala2GIP, in the MPTP-induced neurotoxicity in mice. The observed protective effects are potentially due to reduced oxidative stress and attenuation of dopamine loss in
-
In the course of our ongoing attempts to photolabel alloster
2022-09-30

In the course of our ongoing attempts to photolabel allosteric binding sites of γ-aminobutyric Thiola sale type A (GABAA) receptors, we were met with the need for relatively large (near mg) quantities of recombinant protein. Rather than establishing a stable cell line we sought to optimise the proc
-
We found that silymarin induced more improvement of renal fu
2022-09-30

We found that silymarin induced more improvement of renal functions compared to Rvs. Our results were in agreement with previous studies. The effect of silymarin has been tested in alloxan-induced diabetes mellitus models in rats. Alloxan produces reactive oxygen species which injure renal tissue. S
-
br Acknowledgments br Introduction Non
2022-09-30

Acknowledgments Introduction Non-steroidal anti-inflammatory drugs (NSAIDs) are a common treatment for a number of disease states involving an inflammatory reaction. This group of drugs mediate their anti-inflammatory effects mainly by inhibition of cyclooxygenase (COX), an enzyme of prime imp
-
In the current study we
2022-09-30

In the current study, we report the properties of P. anserina mutants carrying mutations in a gene encoding the bi-functional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2). This enzyme catalyzes two opposite reactions (Pilkis et al., 1995, Rider et al., 2004): synthesi
16104 records 393/1074 page Previous Next First page 上5页 391392393394395 下5页 Last page